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O B J E C T I V E S The aim of this study was to assess the prognostic value of right ventricular (RV)
involvement diagnosed by cardiac magnetic resonance (CMR) early after ST-elevation myocardial infarction
(STEMI).
B A C KG ROUND CMR allows accurate and reproducible RV assessment. However, there is a paucity
of data regarding the prognostic value of RV involvement detected by CMR early after STEMI.
METHOD S Ninety-nine patients (77 men, mean age 57  11 years) who underwent CMR 3 to 5 days
after STEMI treated with primary angioplasty were followed for 1,150  337 days for cardiac events (cardiac
death, nonfatal myocardial infarction [MI], and hospitalizations due to decompensated heart failure). Cox
proportional hazards model was applied in stepwise forward fashion to identify outcome predictors.
Event-free survival was estimated by Kaplan-Meier method and compared between groups by the log-rank
test.
R E S U L T S Cardiac events occurred in 34 patients (7 cardiac deaths, 8 MIs, 26 hospitalizations). By
multivariable analysis, the independent outcome predictors were left ventricular (LV) MI transmurality index
(hazard ratio: 1.03 per 1%; 95% conﬁdence interval: 1.01 to 1.04; p  0.001), RV ejection fraction (RVEF)
(hazard ratio: 1.46 per 10% decrease; 95% conﬁdence interval: 1.05 to 2.02; p 0.03), and RVMI extent (hazard
ratio: 1.50 per each infarcted RV segment; 95% conﬁdence interval: 1.11 to 2.01; p 0.007). Compared with
clinical data (global chi-square  5.2), LV ejection fraction [LVEF] (global chi-square  11.1), RVEF (global
chi-square 17.1), LVMI transmural extent (global chi-square 26.0), and RVMI extent (global chi-square
34.9) improved outcome prediction in sequential Cox model analysis (p  0.05 for all steps). RVEF stratiﬁed
risk in patients with LVEF40% in whom the 4-year event-free survival was 66.7% for RVEF40% and 40.0%
for RVEF 40% (p  0.05).
CONC L U S I O N S The extent of RVMI and RV dysfunction assessed early after STEMI are independent
outcome predictors, which provide incremental prognostic value to clinical data, LV systolic function, and infarct
burden.Measurement of RVEFmay be particularly useful to stratify risk in patientswith depressed LV function after
STEMI. (J Am Coll Cardiol Img 2010;3:1237–46) © 2010 by the American College of Cardiology Foundation
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1238ight ventricular (RV) dysfunction and RV
myocardial infarction (MI) are frequent fac-
tors complicating acute MI. RVMI occurs in
approximately 50% of patients with inferior
I and 10% of patients with anterior MI (1,2).
lthough RV involvement is usually not the focus
f patient care during acute MI, because this
omplication only becomes evident during hemo-
ynamic compromise, it still plays an important
rognostic role. Several studies using different di-
gnostic approaches including electrocardiography,
chocardiography, and radionuclide techniques
valuated the issue (1,3–5). Most of them assessed
he prognostic value of RV involvement during
cute MI in patients who underwent thrombolytic
r no reperfusion therapy. Currently, at skilled centers
brisk (Thrombolysis In Myocardial Infarc-
tion2) epicardial coronary flow is restored
in most patients with ST-segment elevation
myocardial infarction (STEMI) undergoing
primary angioplasty (6). Bowers et al. (7)
showed that in patients with RVMI, com-
plete reperfusion promptly normalizes
RVEF and is associated with improved in-
hospital mortality. However, the long-term
prognostic value of RV involvement in those
patients was not studied. Moreover, most
studies evaluated the prognostic value of
RVMI in inferior STEMI, and there are
limited data regarding the prognostic value
of RVMI in an unselected series of patients
with STEMI.
Despite the fact that cardiac magnetic
resonance (CMR) is the most accurate and
reproducible noninvasive diagnostic tool
for RV evaluation, there is paucity of data
regarding the prognostic value of RV in-
volvement assessed by CMR early after
cute MI. Therefore, we decided to test our hy-
othesis that CMR evaluation of RVMI early after
nterior or inferior STEMI treated with primary
ngioplasty provides prognostic information.
E T H O D S
tudy population. The study was approved by local
thics committee and complied with 1975 Decla-
ation of Helsinki. Informed consent was obtained
rom each patient. Consecutive survivors of first
nterior or inferior STEMI who were treated with
rimary angioplasty with bare metal stent, were
nrolled in the study. STEMI was defined accord-
ng to European Society of Cardiology/American
ion
ction
ionollege of Cardiology Foundation/American Heart issociation/World Heart Foundation criteria in-
luding clinical symptoms, myocardial necrosis
arkers, and typical electrocardiographic changes
8). Exclusion criteria were: 1) contraindication to
MR including magnetic resonance–incompatible
mplants and electric devices, renal insufficiency
creatinine clearance 30 ml/kg/min), inability to
ufficiently hold one’s breath, claustrophobia; 2) any
nown clinical condition that might affect RV
unction independently of MI, including severe
hronic obstructive pulmonary disease, interstitial
ung disease, pulmonary embolism, primary pulmo-
ary hypertension, congenital heart disease or
nown significant valvular disease; and 3) previous
ercutaneous coronary intervention and/or coronary
rtery bypass graft.
lectrocardiography. Twelve-lead standard electro-
ardiography and V4r right precordial lead were
ecorded on admission and interpreted by an expe-
ienced, independent observer blinded to other
esults. STEMI was diagnosed by 1 mm ST-
egment elevation in 2 contiguous leads: V1 to V4
or anterior MI and II, III, and aVF for inferior MI.
VMI was considered present when V4r demon-
trated ST-segment elevation 0.1 mm.
oronary angiography. Coronary angiograms were
valuated by an experienced observer blinded to
ther data. The culprit lesion was defined as the
ost severe and/or the lesion with local dissection
r thrombus. Antegrade epicardial coronary blood
ow in the infarct vessel before and after primary
ngioplasty was evaluated using Thrombolysis In
yocardial Infarction criteria (9). Collateral flow
rom patent vessels to the infarct-related artery was
raded using the Rentrop scale (10).
MR: imaging protocol. Breath-hold electrocar-
iography-gated imaging was performed using a
ardiac phased-array coil on a 1.5-T whole-body
canner (Magnetom Sonata Maestro Class, Sie-
ens, Erlangen, Germany) in left ventricular (LV)
nd RV short-axis and axial views 3 to 5 days after
rimary angioplasty. After scout imaging, cine im-
ging (steady-state free precision gradient echo
echnique; 8-mm slice thickness, no gap, 256 192
atrix, 1.3  1.3-mm2 in-plane resolution) was
cquired. 10 min after infusion of 0.15 mmol/kg
ody weight gadobutrol (Gadovist, Bayer Schering
harma, Berlin, Germany) late gadolinium-
nhanced (LGE) imaging (T1-weighted segmented
nversion-recovery pulse sequence; 8-mm slice
hickness, no gap, 256  192 matrix, 1.3 
.3-mm2 in-plane resolution) was performed withB B R E V I A T I O N S
N D A C R O N YM S
I confidence interval
MR cardiac magnetic
esonance
GE late gadolinium
nhancement
V left ventricular
VEF left ventricular eject
raction
VMI left ventricular
yocardial infarction
Imyocardial infarction
V right ventricular
VEF right ventricular eje
raction
VMI right ventricular
yocardial infarction
TEMI ST-segment elevatnversion time set to null normal myocardium.
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1239MR: image analysis. Cine and LGE images were
ssessed offline (MASS Medis, Leiden, the Neth-
rlands) using 17 LV and 9 RV segment models by
ndependent experienced observers blinded to other
ata. In the presence of discrepancy in qualitative
ssessment, the consensus was reached.
ine images. Endocardial and epicardial borders
ere outlined on short-axis images as previously
escribed (11) (Fig. 1). If the basal slice contained
oth ventricular and atrial myocardium, contours
ere drawn up to their junction and joined by a
traight line through the blood pool. In the basal
lice, if pulmonary valve was visible, only the por-
ion of volume surrounded by trabeculated myocar-
ium below the pulmonary valve level was included.
or RV inflow, the portion blood volume was
xcluded from the RV volume if the surrounding
all was thin and not trabeculated because it was
onsidered to be in the right atrium. LV and RV
nd-diastolic volume, end-systolic volume, myocar-
ial mass, and ejection fraction were computed.
nd-diastolic volume, end-systolic volume, and
yocardial mass were indexed to body surface area.
GE images. LV infarct size was assessed manually with
lanimetry on short-axis slices, delineating hyperen-
anced areas, including surrounded by them hypoen-
ancement regions, considered as microvascular obstruc-
ion. LV infarct and microvascular obstruction size were
xpressed as a percentage of LV myocardial volume. The
VMI transmurality index was calculated as total hyper-
nhanced area divided by total area of infarcted segments.
Figure 1. Example of Volumetric Cardiac Magnetic Resonance M
The endocardial borders of the right ventricle (yellow outline) and
axis view from the atrioventricular valves to the apex to determine caviVMI was defined as the presence of LGE in any
egment of RV free wall, and RVMI extent was assessed
s the number of RV segments with LGE (12) (Fig. 2).
ollow-up. Clinical follow-up was prospectively
erformed every year after CMR. Clinical informa-
ion regarding cardiac death, MI, hospitalizations
ue to decompensated heart failure, and coronary
evascularizations was obtained by telephone inter-
iews with patients, contact with patients’ physi-
ians as well as hospital and administrative records
y individuals blinded to other data. Adverse car-
iac events were defined as cardiac death (i.e., death
f any cardiac cause, including MI, arrhythmia, and
eart failure), nonfatal MI (according to European
ociety of Cardiology/American College of Car-
iology Foundation/American Heart Associa-
ion/World Heart Foundation criteria), and hos-
italizations due to decompensated heart failure
admission to any health care facility due to new
r worsening heart failure requiring intravenous
reatment with inotropic, diuretic, or vasodilator
herapy) (8). When a patient experienced 1
ardiac event, the first event was chosen. In the
ase of 2 simultaneous cardiac events, the worst
vent was chosen (cardiac death  nonfatal MI 
ospitalization).
tatistical analysis. There were no sample size cal-
ulations. Categorical data are presented as num-
ers or percentages and continuous data as mean 
D or median with interquartile range, where
ppropriate. The normal distribution was verified
urements Performed for the Right Ventricle and Left Ventricle
ventricle (red outline) were manually delineated at each short-eas
left
ty areas at end-diastole (shown here) and end-systole.
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1240sing the Shapiro-Wilk test. Categorical variables
ere compared by the Fisher exact test or chi-
quare test and continuous variables by an unpaired
tudent t test or Wilcoxon rank-sum test. Cox
roportional hazards analysis was performed to
etermine the association between variables and
omposite outcomes defined as cardiac death/
onfatal MI/hospitalization due to decompensated
eart failure. Patients who underwent revasculariza-
ion during follow-up were not censored. A hazard
atio with a 95% confidence interval (CI) was
alculated for each variable. For analysis, we se-
ected clinical and CMR-derived parameters that
ight be associated with outcomes from a patho-
hysiologic standpoint. Univariable analysis of se-
ected variables was performed to identify potential
redictors. Finally, multivariable models were cre-
ted to assess the independent predictive value of
V parameters corrected for individual LV param-
ters demonstrating p  0.05 on univariable anal-
sis. To identify independent predictors in each
odel, a forward stepwise multivariable analysis
as performed. Multivariable models were limited
o 3 variables to avoid model overfitting. To deter-
ine the incremental prognostic benefit of CMR-
erived parameters over clinical data, a sequential
Figure 2. Short-Axis LGE Images Showing Contrast Enhancemen
In a patient with anterior ST-segment elevation myocardial infarctio
rior part of the right ventricular (RV) free wall (A), whereas in patien
the inferior and the mid-part of RV free wall. Yellow arrows indicat
wall, and red arrows indicate microvascular obstruction.ox model analysis was performed. Entry and setention was set at p  0.05. The incremental
rognostic value was defined by a significant in-
rease in global chi-square. To test proportional
azards assumptions, a linear regression of partial
esiduals against survival was performed. Absence
f significant correlation (p  0.05) was taken to
ignify that proportional hazards assumptions were
ot violated. Cumulative event rates as a function
ver time was estimated by the Kaplan-Meier
ethod and compared among groups by log-rank
est. The reproducibility for RVEF and RVMI
xtent assessment was determined as mean absolute
ifference (bias) and 95% CI of the mean difference
limits of agreement) according to the Bland-
ltman method. To assess it, CMR images were
valuated by the same observer unaware of previous
esults and by the second observer blinded to the
esults obtained by the first one. Statistical analyses
ere performed using SPSS software (version 12.0,
PSS Inc., Chicago, Illinois). Differences were
onsidered statistically significant at p  0.05.
E S U L T S
aseline characteristics. Of a total of 105 consecutive
atients enrolled in the study, 3 patients had un-
d Microvascular Obstruction Areas
TEMI), late gadolinium enhancement (LGE) is present in the ante-
ith inferior STEMI, LGE areas encompass the inferior (B) or both
E in RV free wall, white arrows indicate LGE in left ventriculart an
n (S
ts w
e LGuccessful CMR: 2 due to respiratory problems and
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1241due to cardiac arrhythmia. Of the remaining 102
atients, follow-up was complete for 99 patients (77
en, mean age 57  11 years), who formed the
tudy group. Among the 3 patients lost to follow-
p, no deaths were identified through the Polish
eath Registry. Patients’ clinical characteristics are
hown in Table 1.
MR. CMR characteristics are summarized in Tables 2
nd 3. Fifty patients had an LV ejection fraction (LVEF)
40% and 23 an RVEF40%. RVMI was found in 26
atients including 10 (15%) with anterior MI and 16
47%) with inferior MI (p 0.001 for MI location). In
atients with RVMI, LGE was detected in 2.0 (inter-
uartile range: 1.0 to 2.3) RV segments. Comparing
atients with and without angiographically visualized
ollateral flow from patent vessels to infarct-related ar-
ery, the former less frequently had an RVEF 40% (2
7%] vs. 21 [29%], p  0.03). No significant difference
etween these groups was found with respect to the
Table 1. Clinical Characteristics
All Patients
(n  99)
Female/male 22/77
Age, yrs 57 11
Current tobacco use, % 32
Hypercholesterolemia, % 92
Hypertension, % 72
Diabetes mellitus, % 20
Family history of CAD, % 36
Body mass index, kg/m2 27.8 3.7
Pre-infarction angina, % 30
Worst Killip-Kimball class: 1/2/3/4 80/17/2/0
Time: chest pain onset to balloon, h 4.8 3.1
Time: door to balloon, min 34 31
Nonsinus rhythm, % 6
Heart rate, beats/min 83 17
Heart rate 100 beats/min, % 15
Anterior/inferior STEMI 65/34
V4r: ST-segment elevation 0.1 mm, % 30
CPKmax, U/l 5,097 4,131
CPK-MBmax, U/l 560 401
TnImax, g/l 74 59
Culprit lesion: LAD/RCA/LCX 65/32/2
TIMI before PCI: 0/1/2/3 81/14/2/2
TIMI after PCI: 0/1/2/3 0/0/17/82
Rentrop scale: 0/1/2/3 72/20/6/1
Single/multivessel disease 53/46
Angiotensin-converting enzyme inhibitors, % 92
Beta-blockers, % 95
Statins, % 91
CAD coronary artery disease; CPKmaxmaximum creatine phosphokinase; CPK
artery; RCA  right coronary artery; RVMI  right ventricular myocardial infarction;revalence of RVMI (4 [15%] vs. 22 [31%], p 0.13).
ntra- and interobserver variability for RVEF was0.5%
95% CI:3.9 to 2.9) and 1.1% (95% CI:2.7 to 4.9),
hereas for RVMI extent analysis 0.1 RV segment
95% CI:0.6 to 0.4) and0.1 RV segment (95% CI:
0.7 to 0.5), respectively.
ollow-up. During 1,150  337 days of follow-up,
ardiac events occurred in 34 patients: 7 cardiac
eaths, 8 nonfatal MIs, and 26 hospitalizations
ue to decompensated heart failure. Eleven pa-
ients were revascularized: 10 percutaneous coro-
ary intervention and 1 coronary artery bypass
raft. Tables 4 and 5 demonstrate the univariable
nd multivariable predictors of follow-up events.
ompared with clinical data, LVEF, RVEF,
VMI transmural extent, and RVMI extent im-
roved prediction of adverse cardiac events (p 
.05 for all sequential steps) (Fig. 3). The 4-year
vent-free survival in patients with an LVEF40%
Event RV
Yes / No
(n  34) / (n  65) p Value
Present / Absen
(n  26) / (n  7
8/26 / 14/51 0.98 8/18 / 14/59
59 10 / 56 12 0.20 57 9 / 57 1
32 / 32 0.82 42 / 29
94 / 91 0.71 88 / 93
79 / 68 0.32 81 / 68
26 / 17 0.39 35 / 15
38 / 35 0.95 42 / 34
27.2 3.3 / 28.1 3.9 0.29 27.4 3.5 / 27.9
35 / 28 0.58 27 / 32
24/8/2/0 / 56/9/0/0 0.06 21/3/2/0 / 59/14/
4.9 3.2 / 4.8 3.0 0.92 4.9 3.9 / 4.8 3
38 37 / 32 27 0.34 33 31 / 34 3
6 / 6 1.0 8 / 5
82 17 / 83 17 0.93 80 14 / 83 1
21 / 12 0.43 8 / 18
24/10 / 41/24 0.60 10/16 / 55/18
41 / 25 0.14 58 / 21
,527 4,203 / 4,872 4,107 0.46 6,588 4,510 / 4,566
620 432 / 529 383 0.29 677 384 / 519
77 57 / 73 61 0.77 90 66 / 69 5
24/10/0 / 41/22/2 0.50 10/16/0 / 55/16/
27/7/0/0 / 54/7/2/2 0.30 24/2/0/0 / 57/12/
0/0/8/26 / 0/0/9/56 0.35 0/0/7/19 / 0/0/10
25/8/1/0 / 47/12/5/1 0.65 22/3/1/0 / 50/17/
16/18 / 37/28 0.47 15/11 / 38/35
88 / 94 0.44 88 / 93
91 / 97 0.34 92 / 95
88 / 92 0.49 88 / 92
maxmaximum creatine phosphokinase-myocardial bound; LAD left anterior arMI
t
3) p Value
0.34
2 0.98
0.31
0.43
0.31
0.18
0.05
3.8 0.60
0.85
0/0 0.04
.3 0.83
1 0.82
0.65
8 0.50
0.34
0.30
0.31
5 3,882 0.03
401 0.08
6 0.12
2 0.0009
2/2 0.10
/63 0.22
5/1 0.45
0.79
0.43
0.60
0.69
-MB tery; LCX left circumﬂex
STEMI  ST-segment elevation myocardial infarction; TnImax  maximum troponin I.
o
(

r
p
e
4
D
T
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e
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n
right ventricular end-diast end
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1242r an LVEF40% was 74% and 51%, respectively
p  0.05), whereas that in patients with an RVEF
40% or an RVEF 40% was 70% and 42%,
espectively (p  0.01). RVEF stratified risk in
atients with LVEF 40% in whom the 4-year
vent-free survival was 66.7% for RVEF 40% and
0.0% for RVEF 40% (p  0.05) (Fig. 4).
netic Resonance Characteristics With Regard to Right Ventricular
All Patients
(n  99)
Even
Yes / No
(n  34) / (n  65)
39 11 34 12 / 41 10
50 65 / 43
75 18 77 18 / 73 18
47 17 52 18 / 44 16
78 21 79 17 / 78 23
28 8 25 8 / 29 8
51 13 47 12 / 54 13
23 38 / 15
55 15 57 16 / 53 14
27 12 31 12 / 25 12
22 15 28 16 / 18 13
63 82 / 54
2.7 (IQR: 0.0–4.9) 3.7 (2.5–6.6) / 1.4 (0.0–4.
ex, % 59 27 72 23 / 52 27
26 44 / 17
/5 segments 73/11/8/3/3/1 19/5/6/2/1/1 / 54/6/2/1/2
LV  left ventricular; LVEDV  left ventricular end-diastolic volume; LVEF  left
ium enhancement; LVMI  left ventricular myocardial infarction; LVMO  left ven
olic volume; RVEF  right ventricular ejection fraction; RVESV  right ventricular
netic Resonance Characteristics With Regard to STEMI Location
STEMI A
Anterior / Inferior
(n  65) / (n  34) p Value
Ye
(n  24
37 11 / 41 12 0.11 34 1
58 / 35 0.20 6
75 19 / 74 17 0.93 75 1
48 18 / 44 16 0.34 51 1
78 20 / 79 23 0.83 75 1
27 7 / 30 9 0.06 25
52 13 / 51 14 0.62 46 1
22 / 26 0.76 4
52 14 / 59 15 0.04 58 1
26 12 / 30 13 0.17 32 1
24 16 / 17 13 0.02 28 1
63 / 65 0.95 7
2.5 (IQR: 0.0–4.9) / 2.9 (IQR: 0.0–4.5) 0.95 3.5 (IQR: 1.4–6.6
x, % 62 26 / 52 29 0.07 71 2
15 / 47 0.002 2
5 segments 55/3/5/1/0/1 / 18/8/3/2/3/0 0.39 19/1/3/0/0/tion myocardial infarction; other abbreviations as in Tables 1 and 2.I S C U S S I O N
his is the first study to demonstrate that RV
ysfunction and RVMI extent detected by CMR
arly after STEMI treated with primary angioplasty
ith stent implantation are independent prog-
osticators of adverse clinical events. The assess-
ocardial Infarction and Adverse Cardiac Events
RVMI
p Value
Present / Absent
(n  26) / (n 73) p Value
0.002 32 11 / 41 11 0.001
0.07 65 / 45 0.12
0.41 81 16 / 72 18 0.04
0.04 55 17 / 44 17 0.003
0.87 87 25 / 75 19 0.01
0.008 25 8 / 29 8 0.08
0.009 44 12 / 54 13 0.001
0.02 38 / 18 0.06
0.23 60 15 / 53 14 0.047
0.04 33 13 / 25 11 0.002
0.001 25 13 / 21 16 0.24
0.01 85 / 56 0.01
0.002 4.0 (2.9–7.4) / 1.6 (0.0–4.3) 0.002
0.001 62 27 / 58 27 0.51
0.007 100 / 0 0.001
0.04 0/11/8/3/3/1 / 73/0/0/0/0/0 0.001
icular ejection fraction; LVESV  left ventricular end-systolic volume; LVLGE 
lar microvascular obstruction; LVSV  left ventricular stroke volume; RVEDV 
-systolic volume; RVMI  right ventricular myocardial infarction.
rior STEMI Inferior STEMI
o
n  41) p Value
Yes / No
(n  10) / (n  24) p Value
9 9 0.10 33 11 / 45 10 0.005
4 0.44 60 / 25 0.12
4 20 0.79 79 9 / 72 16 0.26
6 18 0.37 55 19 / 40 13 0.02
0 23 0.34 88 21 / 75 23 0.12
8 6 0.11 25 7 / 32 9 0.04
5 12 0.007 48 11 / 52 15 0.43
0 0.004 30 / 25 1.00
9 13 0.02 56 15 / 60 15 0.40
3 10 0.003 28 8 / 30 15 0.75
2 14 0.14 30 15 / 12 8 0.001
6 0.21 100 / 50 0.006
.4 (IQR: 0.0–4.3) 0.08 4.9 (IQR: 3.4–6.4) / 0.7 (IQR: 0.0–3.7) 0.003
8 26 0.049 75 22 / 43 26 0.002
2 0.48 100 / 25 0.001
6/2/2/1/0/0 0.45 0/4/3/2/1/0 / 18/4/0/0/2/0 0.001Table 2. Cardiac Mag My
t
LVEF, %
LVEF 40%, %
LVEDV index, ml/m2
LVESV index, ml/m2
LV mass index, g/m2
LVSV index, ml/m2
RVEF, %
RVEF 40%, %
RVEDV index, ml/m2
RVESV index, ml/m2
LVLGE index, %
LVMO present, %
LVMO index, % 2)
LVMI transmurality ind
RVMI present, %
RVMI extent: 0/1/2/3/4 /0
IQR  interquartile range; ventr
left ventricular late gadolin tricuTable 3. Cardiac Mag
nte
s / N
) / (
LVEF, % 2 / 3
LVEF 40%, % 7 / 5
LVEDV index, ml/m2 8 / 7
LVESV index, ml/m2 9 / 4
LV mass index, g/m2 4 / 8
LVSV index, ml/m2 8 / 2
RVEF, % 2 / 5
RVEF 40%, % 2 / 1
RVEDV index, ml/m2 6 / 4
RVESV index, ml/m2 3 / 2
LVLGE index, % 7 / 2
LVMO present, % 5 / 5
LVMO index, % ) / 1
LVMI transmurality inde 4 / 5
RVMI present, % 1 / 1
RVMI extent: 0/1/2/3/4/ 1 / 3
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1243ent of RVEF and RVMI enhances the prog-
ostication of CMR-derived LV parameters and
rovides incremental prognostic value to clinical
ata, LV systolic dysfunction, and infarct burden.
oreover, RVEF allows risk stratification of
atients after STEMI, especially those with an
VEF 40%.
So far, several trials have showed that after
TEMI either RV dysfunction or RVMI are im-
ortant determinants of short- and long-term prog-
osis (1,3–5). The present study demonstrates that
V involvement diagnosed early after STEMI is a
trong outcome predictor and that both RVEF and
VMI have an important prognostic impact irre-
pective of LVMI burden. Compared with previous
tudies, cardiac mortality in the current trial was
ow, which may have several plausible explanations.
irst, previous observations were derived predomi-
antly from STEMI patients treated with throm-
olysis or no reperfusion therapy, whereas in the
resent study, the majority of subjects underwent
rimary angioplasty within 6 h after STEMI symp-
om onset. Second, in the current trial, primary
ngioplasty with stent implantation successfully es-
ablished normal Thrombolysis In Myocardial In-
arction grade 3 epicardial flow in most individuals.
s previously demonstrated, patients with RVMI
ho have timely and complete reperfusion of right
oronary artery have an excellent short-term prog-
osis (7). Finally, patients with severe heart/
espiratory failure who were unable to undergo
MR early after STEMI, were excluded. To our
nowledge, we are the first to show that both RV
ysfunction and RVMI extent are independently
ssociated with clinical outcomes. It may be due to
he fact that RV involvement was previously diag-
osed by electrocardiography, echocardiography, or
adionuclide angiography, but not CMR, which,
eing actually the gold standard for RV assessment,
as been performed only in 2 studies evaluating the
rognostic value of RV involvement after MI
11,13). In the first study, Larose et al. (11) dem-
nstrated by univariable analysis that both RVMI
nd RVEF were associated with clinical outcomes.
owever, by multivariable analysis, only RVEF,
ut not RVMI, determined prognosis. Moreover, in
he second study, the prognostic value of RVMI
as not confirmed by Hombach et al. (13), who
erformed CMR early after acute MI. This discrep-
ncy with our findings may be related to shorter
ollow-up, lower prevalence of RVMI, and a lower
umber of observed events in those trials. As
reviously reported, our data demonstrate that as- bessment of RV involvement enhances prognostica-
ion after acute MI (1,3–5,11). In the current study,
Table 4. Univariable Predictors of Adverse Cardiac Events
Variable
Univariab
Hazard Ratio (95%
Male 0.84 (0.38–1.86
Age, yrs 1.02 (0.99–1.05
Current tobacco use 1.01 (0.49–2.07
Hypercholesterolemia 1.41 (0.34–5.89
Hypertension 1.7 (0.74–3.91
Diabetes mellitus 1.49 (0.69–3.19
Family history of CAD 1.08 (0.54–2.16
Body mass index, kg/m2 0.94 (0.85–1.04
Pre-infarction angina 1.28 (0.63–2.60
Worst Killip-Kimball class 2.26 (1.19–4.32
Time: chest pain onset to balloon, h 1.01 (0.91–1.13
Time: door to balloon, min 1.01 (1.00–1.02
Nonsinus rhythm 1.11 (0.26–4.66
Heart rate, beats/min 1.00 (0.98–1.02
Heart rate 100 beats/min 1.48 (0.65–3.41
Anterior STEMI 1.53 (0.73–3.22
Inferior STEMI 0.65 (0.31–1.58
V4r: ST-segment elevation 0.1 mm 2.00 (1.01–3.97
CPKmax per 100 U/l 1.00 (0.96–1.05
CPK-MBmax per 10 U/l 1.01 (0.97–1.05
TnImax per 10 g/l 1.05 (0.79–1.39
TIMI 0 before PCI 1.32 (0.58–3.05
TIMI 3 after PCI 0.54 (0.24–1.19
Rentrop 0 1.04 (0.49–2.23
Multivessel disease 1.25 (0.64–2.46
Angiotensin-converting-enzyme inhibitors 0.54 (0.19–1.52
Beta-blockers 0.36 (0.11–1.17
Statins 0.67 (0.24–1.9)
LVEF 40% 2.17 (1.08–4.38
LVEF per 10% decrease 1.56 (1.15–2.11
LVEDV index per 1 ml/m2 1.01 (0.99–1.03
LVESV index per 1 ml/m2 1.02 (1.00–1.04
LVSV index per 1 ml/m2 decrease 1.07 (1.02–1.14
LVmass index per 1 g/m2 1.00 (0.99–1.02
RVEF 40% 2.66 (1.33–5.33
RVEF per 10% decrease 1.69 (1.27–2.25
RVEDV index per 1 ml/m2 1.01 (0.99–1.04
RVESV index per 1 ml/m2 1.03 (1.00–1.05
LVLGE index, % 1.03 (1.01–1.05
LVMI transmurality index, % 1.02 (1.01–1.04
LVMO present 3.1 (1.29–7.53
LVMO index, % 1.06 (1.01–1.11
RVLGE present 2.82 (1.43–5.55
RVLGE segment number 1.51 (1.18–1.92
CI  conﬁdence interval; LV  left ventricular; PCI  percutaneous coron
Thrombolysis In Myocardial Infarction; other abbreviations as in Tables 1, 2, anle Predictors
CI) p Value
) 0.67
) 0.18
) 0.98
) 0.64
) 0.21
) 0.31
) 0.83
) 0.20
) 0.50
) 0.01
) 0.87
) 0.31
) 0.89
) 0.92
) 0.35
) 0.26
) 0.26
) 0.047
) 0.95
) 0.63
) 0.74
) 0.51
) 0.12
) 0.92
) 0.52
) 0.24
) 0.09
0.45
) 0.03
) 0.004
) 0.33
) 0.02
) 0.005
) 0.95
) 0.006
) 0.001
) 0.23
) 0.04
) 0.001
) 0.001
) 0.01
) 0.02
) 0.003
) 0.001
ary intervention; TIMI 
d 3.oth RVEF and RVMI extent improved risk as-
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1244essment after STEMI; in particular, RVEF strat-
fied risk in subjects with an LVEF 40%. Inter-
stingly, biventricular dysfunction occurred in
0% of individuals and was associated with the
ighest annualized event rate, reaching 15%. It
mphasizes the need to assess RV function after
TEMI, especially in those who have depressed
V function.
The present study confirms previous observa-
ions that RV systolic dysfunction is predomi-
antly related to LV systolic dysfunction in
nterior STEMI and to RVMI in inferior
Clinical
5.2
Clinical
+LVEF
11.1
p=0.02 p=0.02
Global χ2
0
5
10
15
20
25
30
35
Figure 3. Prognostic Value of Clinical and Cardiac Magnetic Res
Compared with clinical data, left ventricular ejection fraction (LVEF)
infarction (LVMI) transmural extent and right ventricular myocardial
Table 5. Multivariable Models for Prediction of Adverse Cardiac
Model Variables Tested Ha
1 LVEF per 10% decrease
RVEF per 10% decrease
RVLGE segment number
2 LVLGE index, %
RVEF per 10% decrease
RVLGE segment number
3 LVMO index, %
RVEF per 10% decrease
RVLGE segment number
4 LVMI transmurality index, %
RVEF per 10% decrease
RVLGE segment number
Abbreviations as in Tables 2, 3, and 4.deﬁned as cardiac death, nonfatal myocardial infarction, and/or hospitaTEMI (3,14). Our data suggest that in patients
ith inferior STEMI, adverse cardiac events may
e more strongly associated with RVMI than
ith RVEF, which is in line with early recovery
f RV function after successful reperfusion of
nferior STEMI (7). Conversely, in patients with
nterior STEMI, the outcome was related to
epressed RVEF, but not RVMI. This may be
xplained by the fact that, if present, the area of
V necrosis accompanying anterior STEMI is
mall. Recently, it was demonstrated that in
uccessfully reperfused anterior STEMI, RVMI
p=0.003 p=0.003
ical
EF
EF
7.1
Clinical
+LVEF
+RVEF
+LVMI
26
Clinical
+LVEF
+RVEF
+LVMI
+RVMI
34.9
nce Data in Sequential Cox Model Analysis
ht ventricular ejection fraction (RVEF), left ventricular myocardial
rction (RVMI) extent improve prediction of adverse cardiac events
nts
Multivariable Predictors
Ratio (95% CI) p Value Chi-Square
9 (1.27–2.25) 0.001 13.9
3 (1.01–1.05) 0.005
9 (1.00–1.92) 0.049 22.4
6 (1.02–1.80) 0.04
9 (1.27–2.25) 0.001 13.9
3 (1.01–1.04) 0.001
6 (1.05–2.02) 0.03 29.8
0 (1.11–2.01) 0.007Clin
+LV
+RV
1
ona
, rig
infaEve
zard
1.6
1.0
1.3
1.3
1.6
1.0
1.4
1.5lization due to decompensated heart failure.
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1245ffected only 2% of RV mass despite the large
xtent of RV myocardium at risk (15). There may
e several plausible reasons for the preservation of
he RV wall in the settings: its low oxygen
emand, its ability to increase oxygen extraction,
omogeneous transmural perfusion, extensive
ollateral system, and complete left anterior de-
cending artery reperfusion (15,16).
tudy limitations. First, although CMR may be
onsidered the gold standard for RVEF assessment,
here can be difficulties in discriminating the RV
rom the right atrium wall at the tricuspid valve
evel in the short-axis view due to through-plane
ovement of the atrioventricular groove. To better
iscern it, we carefully observed heart chamber
otion and used dedicated software to evaluate
ross section lines of short-axis planes in apical
-chamber and RV cine images. Furthermore,
VEF as assessed by CMR is influenced by loading
onditions and may not solely reflect contractility.
nfortunately, echocardiographic assessment of RV
unction and evaluation of systolic pulmonary pres-
ure were not performed to help clarify the mech-
nism of RV dysfunction. The relatively low spatial
esolution for LGE imaging in the thin RV wall,
he difficulty to separate infarcted tissue from sur-
ounding fat, and partial volume effect of fat signal
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Figure 4. Kaplan-Meier Event-Free Survival Curves With Respec
Both cardiac magnetic resonance–derived right ventricular ejection
extent stratify risk of adverse cardiac events deﬁned as cardiac deat
decompensated heart failure. LGE  late gadolinium enhancement;
right ventricular.ay limit accurate detection of RVMI (12). More- 3ver, the myocardium at risk for both ventricles was
ot assessed, not allowing us to determine the
yocardial salvage. Finally, due to the inability to
erform CMR early after STEMI complicated by
evere heart/respiratory failure, the present study
ay be biased toward a less complicated cohort of
atients.
O N C L U S I O N S
MR is an important diagnostic tool for assessing
ot only LV but also RV involvement early after
TEMI. The extent of RVMI and RV dysfunction
fter primary angioplasty with stent implantation
or STEMI are powerful independent predictors
f adverse clinical outcomes and provide incre-
ental prognostic information to clinical data,
V systolic dysfunction, and infarct burden.
easurement of RVEF should be considered in
ll patients with STEMI and may be particularly
seful to further stratify risk in those with de-
ressed LV function.
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